Table 3.
Relationship between PSCA and Oct-4 expression, clinicopathological characteristics, and average survival of gallbladder adenocarcinoma patients.
| Clinicopathological characteristics | Samples (n) | Average survival (month) | P value |
|---|---|---|---|
| Sex | |||
| Male | 19 | 10.0 (4–16) | 0.910 |
| Female | 48 | 10.0 (4–18) | |
| Age (years) | |||
| ≤45 | 11 | 8.0 (4–14) | 0.121 |
| >45 | 56 | 10.0 (4–18) | |
| Pathological types | |||
| Adenoma | 8 | 12.0 (8–18) | 0.031 |
| Well | 20 | 10.0 (4–18) | |
| Moderately | 20 | 10.0 (4–18) | |
| Poorly | 12 | 8.0 (4–10) | |
| Mucinous A. | 7 | 10.0 (6–16) | |
| Tumor size (cm) | |||
| <2 | 20 | 14.0 (4–18) | 0.003 |
| ≥2 | 47 | 8.0 (4–18) | |
| Lymph node metastasis | |||
| No | 36 | 12.0 (4–18) | 0.005 |
| Yes | 31 | 8.0 (4–18) | |
| T stages | |||
| T1 | 10 | 12.6 (6–18) | 0.003 |
| T2 | 26 | 11.4 (4–18) | |
| T3 | 23 | 9.5 (4–18) | |
| T4 | 8 | 7.0 (4–10) | |
| Operative procedure | |||
| Radical | 26 | 12.7 (4–18) | <0.001 |
| Nonradical | 41 | 8.9 (4–16) | |
| PSCA | |||
| + | 35 | 9.3 (4–18) | 0.013 |
| − | 32 | 11.6 (4–18) | |
| Oct-4 | |||
| + | 37 | 9.5 (4–18) | 0.029 |
| − | 30 | 11.5 (4–18) | |
| PSCA + Oct-4 | |||
| PSCA (+) Oct-4 (+) | 24 | 8.9 (4–18) | 0.021 |
| PSCA (+) Oct-4 (−) | 11 | 10.7 (4–16) | |
| PSCA (−) Oct-4 (+) | 13 | 9.7 (4–16) | |
| PSCA (−) Oct-4 (−) | 19 | 12.5 (6–18) |